Effect of Alirocumab on Mortality After Acute Coronary Syndromes: An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial

BACKGROUND: Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demonstrated reductions in major adverse cardiovascular events, but not death. We assessed the effects of alirocumab on death after index acute coronary syndrome. METHODS: ODYSSEY OUTCOMES (Evaluation of...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Circulation
Main Authors: Steg, Philippe Gabriel, Szarek, Michael, Bhatt, Deepak L., Bittner, Vera A., Brégeault, Marie-France, Dalby, Anthony J., Diaz, Rafael, Edelberg, Jay M., Goodman, Shaun G., Hanotin, Corinne, Harrington, Robert A., Jukema, J. Wouter, Lecorps, Guillaume, Mahaffey, Kenneth W., Moryusef, Angèle, Ostadal, Petr, Parkhomenko, Alexander, Pordy, Robert, Roe, Matthew T., Tricoci, Pierluigi, Vogel, Robert, White, Harvey D., Zeiher, Andreas M., Schwartz, Gregory G.
Format: Artigo
Sprog:Inglês
Udgivet: Lippincott Williams & Wilkins 2019
Fag:
Original Research Articles
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6661243/
https://ncbi.nlm.nih.gov/pubmed/31117810
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCULATIONAHA.118.038840
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker